Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Clinical trial NCT02865811 · COMPLETED
Trial details
- NCT number
- NCT02865811
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-15
- Primary completion
- 2020-08-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.